Success Metrics

Clinical Success Rate
55.6%

Based on 5 completed trials

Completion Rate
56%(5/9)
Active Trials
0(0%)
Results Posted
160%(8 trials)
Terminated
4(40%)

Phase Distribution

Ph phase_2
2
20%
Ph phase_3
6
60%
Ph phase_1
1
10%

Phase Distribution

1

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
6(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(5)
Terminated(4)
Other(1)

Detailed Status

Completed5
Terminated4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
55.6%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 22 (22.2%)
Phase 36 (66.7%)

Trials by Status

completed550%
unknown110%
terminated440%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

NCT03437278
terminatedphase_3

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

NCT04984876
completedphase_3

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

NCT03907878
completedphase_3

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

NCT03580356
terminatedphase_3

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

NCT04210843
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03437278Phase 2

Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

Completed
NCT04984876Phase 3

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Terminated
NCT03907878Phase 3

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

Completed
NCT03580356Phase 3

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

Completed
NCT04210843Phase 3

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Terminated
NCT04513548Phase 1

Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria

Terminated
NCT05024058Phase 3

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Terminated
NCT03580369Phase 3

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Completed
NCT04903613

Global Managed Access Program Cohort for Ligelizumab in CSU

Unknown
NCT02649218Phase 2

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10